

Resource Summary Report

Generated by [dkNET](#) on Aug 5, 2026

Hsd:Athymic Nude-Foxn1^{nu}/Foxn1 +

RRID:IMSR_ENV:HSD-070

Type: Organism

Proper Citation

RRID:IMSR_ENV:HSD-070

Organism Information

URL: <https://www.envigo.com/model/hsd-athymic-nude-foxn1nu-foxn1>

Proper Citation: RRID:IMSR_ENV:HSD-070

Description: Mus musculus with name Hsd:Athymic Nude-Foxn1^{nu}/Foxn1 + from IMSR.

Species: Mus musculus

Notes: gene symbol note: forkhead box N1; outbred stock|mutant stock: Foxn1

Affected Gene: forkhead box N1

Genomic Alteration: nude

Catalog Number: ENV:HSD-070

Database: Envigo an Inotiv Company

Database Abbreviation: ENV

Availability: live

Organism Name: Hsd:Athymic Nude-Foxn1^{nu}/Foxn1 +

Record Creation Time: 20250513T061850+0000

Record Last Update: 20260801T055436+0000

Ratings and Alerts

No rating or validation information has been found for Hsd:Athymic Nude-Foxn1^{nu}/Foxn1 +.

No alerts have been found for Hsd:Athymic Nude-Foxn1^{nu}/Foxn1 +.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Envigo an Inotiv Company

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Mansi R, et al. (2025) Pyridyl-Ala in the third position of radiolabeled somatostatin antagonists: the effect of regioisomeric substitution. EJNMMI radiopharmacy and chemistry, 10(1), 35.

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. Molecular cancer therapeutics, 24(6), 843.

Basaco Bernabeu T, et al. (2024) 61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(9), 1427.

Basaco Bernabeu T, et al. (2024) Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study. Frontiers in nuclear medicine, 4, 1481343.